<div id="readability-page-1"><div><ul><li>Athira Pharma Inc reported a quarterly adjusted loss of $1.68​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-7.50. The mean expectation of two analysts for the quarter was for a loss of $1.22 per share. Wall Street expected results to range from $-1.24 to $-1.20 per share.</li><li>Reported revenue was zero​; analysts expected zero. </li><li>Athira Pharma Inc's reported EPS for the quarter was a loss of $1.68​.</li><li>The company reported a quarterly loss of $6.61 million.</li><li>Athira Pharma Inc shares had fallen by 3.1% this quarter and lost 31.7% so far this year.</li></ul>FORECAST CHANGES<ul><li>The mean earnings estimate of analysts had risen by about 11.6% in the last three months.​ </li><li>In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.</li></ul>RECOMMENDATIONS<ul><li>The current average analyst rating on the shares is &#34;hold&#34; and the breakdown of recommendations is no &#34;strong buy&#34; or &#34;buy,&#34; 2 &#34;hold&#34; and no &#34;sell&#34; or &#34;strong sell.&#34; The average consensus recommendation for the biotechnology &amp; medical research peer group is &#34;buy.&#34;</li></ul>This summary was machine generated from LSEG data November 7 at 07:42 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)<div><table><tbody><tr><td>QUARTER ENDING</td><td>ESTIMATE </td><td>ACTUAL</td><td>BEAT, MET, MISSED</td></tr><tr><td>Sep. 30 2025 </td><td>-1.22</td><td>-1.68</td><td>Missed</td></tr><tr><td>Jun. 30 2025 </td><td>-1.80</td><td>-1.80</td><td>Met</td></tr><tr><td>Mar. 31 2025 </td><td>-2.40</td><td>-2.30</td><td>Beat</td></tr><tr><td>Dec. 31 2024 </td><td>-4.41</td><td>-3.90</td><td>Beat</td></tr></tbody></table></div></div></div>

ATHA

Athira Pharma Inc reported a quarterly adjusted loss of $1.68 per share for the quarter ended September 30, exceeding last year's loss of $7.50 per share. Analysts had expected a loss of $1.22 per share. The company reported zero revenue and a quarterly loss of $6.61 million. Athira's shares fell by 3.1% this quarter and 31.7% year-to-date. The average analyst rating is "hold" with no strong buy recommendations. The earnings estimates have risen by 11.6% in the last three months, with no revisions in the last 30 days.

Athira Pharma Inc reports results for the quarter ended September 30 - Earnings Summary